[1] Interim guidance for country validation of viral hepatitis elimination. Geneva: World Health Organization. License: CC BY-NC-SA 30 IGO, 2021. [2] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol , 2018, 3(6): 383-403. [3] 尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版). 实用肝脏病杂志. 2023: 457-478. [4] Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut, 2015, 64(12): 1972-1984. [5] Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife, 2012, 3. [6] Xia Y, Guo H. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. Antiviral Res, 2020, 180: 104824. [7] Wei L, Ploss A. Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation. Nat Microbiol, 2020, 5(5): 715-726. [8] Wei L, Ploss A. Hepatitis B virus cccDNA is formed through distinct repair processes of each strand. Nat Commun, 2021, 12(1): 1591. [9] Zoulim F, Testoni B. Eliminating cccDNA to cure hepatitis B virus infection. J Hepatol, 2023, 78(4): 677-680. [10] Seeger C, Sohn JA. Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids, 2014, 3(12): e216. [11] Wang L, Zhu Q, Zhang JD, et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor. J Hepatol, 2023, 78(4): 742-753. [12] Hong X, Kim ES, Guo H. Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B. Hepatology, 2017, 66(6): 2066-2077. [13] 陈娟, 黄爱龙. 从HBV cccDNA角度谈乙型肝炎的功能性治愈. 临床肝胆病杂志, 2022, 38(08): 1716-1720. [14] Wei ZQ, Zhang YH, Ke CZ, et al. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation. World J Gastroenterol, 2017, 23(34): 6252-6260. [15] Decorsière A, Mueller H, van Breugel PC, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature, 2016, 531(7594): 386-389. [16] Cheng ST, Hu JL, Ren JH, et al. Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx. J Hepatol, 2021, 74(3): 522-534. [17] Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov, 2019, 18(11): 827-844. [18] Huang Q, Zhou B, Cai D, et al. Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients. Hepatology, 2021, 73(1): 41-52. [19] Tsiang M, Gibbs CS. Analysis of hepatitis B virus dynamics and its impact on antiviral development. Methods Mol Med, 2004, 96: 361-377. [20] Tang Y, Liang H, Zeng G, et al. Advances in new antivirals for chronic hepatitis B. Chin Med J (Engl),2022, 135(5): 571-583. |